Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) by 42.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,167 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,845 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $2,155,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Jazz Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after purchasing an additional 57,949 shares during the period. JPMorgan Chase & Co. boosted its position in Jazz Pharmaceuticals by 2.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,377,061 shares of the specialty pharmaceutical company’s stock worth $526,855,000 after acquiring an additional 87,895 shares during the period. Wellington Management Group LLP boosted its position in Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after acquiring an additional 184,124 shares during the period. State Street Corp boosted its position in Jazz Pharmaceuticals by 0.6% during the 1st quarter. State Street Corp now owns 2,345,235 shares of the specialty pharmaceutical company’s stock worth $365,083,000 after acquiring an additional 14,293 shares during the period. Finally, Samlyn Capital LLC boosted its position in Jazz Pharmaceuticals by 28.1% during the 2nd quarter. Samlyn Capital LLC now owns 1,203,559 shares of the specialty pharmaceutical company’s stock worth $187,767,000 after acquiring an additional 264,146 shares during the period. Institutional investors and hedge funds own 89.79% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.8 %

Shares of Jazz Pharmaceuticals stock opened at $156.47 on Tuesday. The stock’s fifty day moving average is $153.64 and its 200-day moving average is $150.08. The firm has a market capitalization of $9.85 billion, a PE ratio of -521.57, a price-to-earnings-growth ratio of 0.89 and a beta of 0.74. The company has a quick ratio of 2.27, a current ratio of 3.16 and a debt-to-equity ratio of 2.07. Jazz Pharmaceuticals plc has a 12-month low of $125.36 and a 12-month high of $169.98.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last announced its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.18. The company had revenue of $940.65 million for the quarter, compared to analyst estimates of $939.88 million. Jazz Pharmaceuticals had a positive return on equity of 30.71% and a negative net margin of 0.52%. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.24 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Samantha Pearce sold 531 shares of the company’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $159.59, for a total transaction of $84,742.29. Following the transaction, the senior vice president now directly owns 11,309 shares of the company’s stock, valued at $1,804,803.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Samantha Pearce sold 531 shares of the company’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $159.59, for a total transaction of $84,742.29. Following the transaction, the senior vice president now directly owns 11,309 shares of the company’s stock, valued at $1,804,803.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $150.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now directly owns 372,028 shares in the company, valued at $55,804,200. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,258 shares of company stock valued at $2,817,148. Company insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of analyst reports. Royal Bank of Canada boosted their price target on Jazz Pharmaceuticals from $206.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, November 10th. Needham & Company LLC reduced their price target on Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating for the company in a research report on Thursday, November 10th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 21st. Finally, The Goldman Sachs Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $192.00 to $190.00 in a research report on Thursday, December 8th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $202.33.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.